Thomas C. K. Yuen - 10 Aug 2021 Form 3 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Reporting relationship
Director
Issuer ticker
PMCB
Reported as of
10 Aug 2021
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
31 Aug 2021, 18:24:19 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Thomas C.K. Yuen

Key filing fact

Thomas C. K. Yuen filed Form 3 for PharmaCyte Biotech, Inc. (PMCB) on 31 Aug 2021.

Key facts

  • This page summarizes Thomas C. K. Yuen's Form 3 filing for PharmaCyte Biotech, Inc. (PMCB).
  • 0 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 31 Aug 2021, 18:24.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PMCB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,667
Date
10 Aug 2021
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMCB holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
334
Exercise price
$87.00
Footnotes
F1, F2
PMCB holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
334
Exercise price
$80.85
Footnotes
F1, F2
PMCB holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
334
Exercise price
$60.60
Footnotes
F1, F2
PMCB holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
334
Exercise price
$36.00
Footnotes
F1, F2
PMCB holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
10 Aug 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
334
Exercise price
$26.55
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").

Footnote F2

The exercise price has been adjusted to reflect the Reverse Split.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .